A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct.

by Christopher J Lynch, Adam D Cawte, Carolyn M Millar, David Rueda, David A Lane
Published 2017-01-01

Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.

by Anna P Andreou, Maria Efthymiou, Yao Yu, Helena R Watts, Faruq H Noormohamed, Daqing Ma, David A Lane, James T B Crawley
Published 2015-01-01